Hong A Ram, Kim Jung Hee, Park Seung Shin, Kong Sung Hye, Choi Hyung Jin, Kim Yong Hwy, Shin Chan Soo
Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea.
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
J Korean Neurosurg Soc. 2022 May;65(3):439-448. doi: 10.3340/jkns.2021.0067. Epub 2022 Feb 21.
Craniopharyngiomas (CPs) are associated with hypothalamic damage that causes hypothalamic obesity, however, the mechanisms underlying CP-related postoperative weight gain remain debatable. This study aimed to elucidate whether the major determinant of postoperative weight gain in patients with CP is hypothalamic injury or steroid replacement therapy.
We included 48 adult patients with CP (age ≥18 years) who underwent transsphenoidal surgery between 2010 and 2018 in a single tertiary center, and whose body weight was measured pre- and postoperatively (<120 days after the surgery). We recruited 144 age- and body mass index-matched patients with non-functioning pituitary adenoma (NFPA) as controls.
Patients with CP experienced greater postoperative weight gain than patients with NFPA (3.0±5.1 vs. 0.1±3.6 kg, p<0.001). The prevalence of postoperative steroid use was significantly higher in patients with CP than in those with NFPA (89.6% vs. 34.0%, p<0.001). Steroid replacement therapy and CP were associated with postoperative weight gain after adjusting for covariates in overall patients (p=0.032 and 0.007, respectively). In subgroup analysis with postoperative steroid users, weight gain was significantly greater in patients with CP (n=43, 0.96±0.25 kg/month) than in patients with NFPA (n=49, 0.26±0.23 kg/month) even after adjusting for the daily steroid dose (p=0.048).
Patients with CP experience greater postoperative weight gain than those with NFPA. Hypothalamic damage itself as well as steroid replacement may contribute to the postoperative weight gain in patients with CP.
颅咽管瘤(CPs)与导致下丘脑性肥胖的下丘脑损伤有关,然而,CP相关术后体重增加的潜在机制仍存在争议。本研究旨在阐明CP患者术后体重增加的主要决定因素是下丘脑损伤还是类固醇替代疗法。
我们纳入了48例成年CP患者(年龄≥18岁),他们于2010年至2018年在单一的三级中心接受了经蝶窦手术,并且在术前和术后(手术后<120天)测量了体重。我们招募了144例年龄和体重指数匹配的无功能垂体腺瘤(NFPA)患者作为对照。
CP患者术后体重增加比NFPA患者更多(3.0±5.1 vs. 0.1±3.6 kg,p<0.001)。CP患者术后使用类固醇的患病率显著高于NFPA患者(89.6% vs. 34.0%,p<0.001)。在对所有患者的协变量进行调整后,类固醇替代疗法和CP与术后体重增加相关(分别为p=0.032和0.007)。在对术后使用类固醇的患者进行亚组分析中,即使在调整了每日类固醇剂量后,CP患者(n=43,0.96±0.25 kg/月)的体重增加也显著大于NFPA患者(n=49,0.26±0.23 kg/月)(p=0.048)。
CP患者术后体重增加比NFPA患者更多。下丘脑损伤本身以及类固醇替代可能导致CP患者术后体重增加。